|
Company Overview
Yaupon Therapeutics is a privately held specialty pharmaceutical
company that develops small molecule pharmaceuticals licensed from
under-served academic laboratories. The company has four products in
development, with one compound in pivotal studies, one compound in phase
2 and additional compounds that will enter the clinic in 12 months. The
company's business philosophy is to build a highly capital efficient
organization that leverages the NIH competitive grant system to offset
research expenses and to validate its technology. The model emphasizes
strong academic collaborations that lead to the licensing and development
of unique products with proof of principle and millions of academic
research dollars behind them. To date Yaupon has received over $15 million
in government support and over $20 million in venture capital.
|
